EyeYon Medical is an Israeli clinical-stage ophthalmic technology company focused on developing and commercializing innovative solutions for severe eye conditions. Their portfolio includes the EndoArt®, an artificial endothelial layer implant designed as a minimally invasive alternative to corneal transplantation for patients with chronic corneal edema. The company is also advancing novel therapeutic approaches for glaucoma and other ophthalmic indications, aiming to significantly improve patient outcomes and address unmet medical needs in eye care.
The headquarters serves as the primary center for EyeYon Medical's research and development, corporate administration, clinical operations management, and strategic global planning.
Located within a prominent science and technology park, the facility is equipped with advanced R&D laboratories and likely includes specialized environments for medical device development and pre-clinical testing. Specific architectural highlights are not publicly detailed.
The work environment at EyeYon Medical is characterized by innovation, collaboration, and a strong scientific focus, typical of a cutting-edge medical technology company. Employees are driven by the mission to develop impactful ophthalmic treatments.
The Ness Ziona headquarters is pivotal to EyeYon Medical's operations, anchoring its innovative R&D efforts within Israel's dynamic life sciences ecosystem and serving as the command center for its global ambitions.
EyeYon Medical orchestrates its global activities, including extensive clinical trials, regulatory submissions, and market development strategies, primarily from its headquarters in Israel. The company is expanding its international reach through strategic partnerships for the distribution and commercialization of its ophthalmic products, particularly EndoArt®, in key markets across Europe (CE Mark approved), Asia, and North America (FDA IDE pivotal study ongoing).
HaEshel St 7, Park Tamar
Ness Ziona
Central District
Israel
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, EyeYon Medical' leadership includes:
EyeYon Medical has been backed by several prominent investors over the years, including:
In the last 12-18 months, EyeYon Medical strengthened its leadership by appointing Dr. Nir Satchi Fainaro as Chief Operating Officer. Publicly available information does not indicate other major executive hires or departures within the immediate last 12 months.
Discover the tools EyeYon Medical uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
EyeYon Medical's email addresses commonly follow standard corporate patterns. The most probable formats involve combinations of the employee's first name and last name initial, or full first name.
[first_initial][last]@eyeyon-medical.com
Format
nferera@eyeyon-medical.com
Example
75%
Success rate
BioSpace / PR Newswire • September 7, 2023
EyeYon Medical presented compelling two-year follow-up data from the first-in-human study of its EndoArt® implant at the ESCRS Congress, demonstrating sustained safety, efficacy, and significant improvements in corneal thickness and visual acuity for patients suffering from corneal edema....more
GlobeNewswire • May 9, 2023
EyeYon Medical appointed Dr. Nir Satchi Fainaro as its Chief Operating Officer. Dr. Satchi Fainaro brings over 20 years of experience in the biotech industry to lead the company's operations, R&D, and manufacturing efforts....more
Cision PR Newswire • January 5, 2023
EyeYon Medical successfully enrolled the first patient in its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal study for EndoArt®. This marks a significant step towards bringing the innovative corneal implant to the U.S. market....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including EyeYon Medical, are just a search away.